Table 3 Summary of cases reviewed

From: Morphologic and immunohistochemical evaluation of splenic hematopoietic proliferations in neoplastic and benign disorders

 

# (%)

Neoplastic myeloid disorders

43 (100)

 CMPD

29 (67)

CIMF

10 (23)

CML

11 (26)

PV

5 (12)

ET

1 (2)

 MDS/MPD

3 (7)

CMML

2 (5)

JMML

1 (2)

 MDS

2 (5)

 AML

9 (21)

 Mastocytosis

2 (5)

Benign

37 (100)

 Autoimmune

 

ITP

12 (32)

AIHA

4 (11)

 TTP/HUS

3 (8)

 Post-BMT

6 (16)

 Other

10 (27)

Lymphoid neoplasms

2 (6)

  1. CMPD=chronic myeloproliferative disorder; CIMF=chronic idiopathic myelofibrosis; CML=chronic myelogenous leukemia; PV=polycythemia vera; ET=essential thrombocythemia; CMML=chronic myelomonocytic leukemia; JMML=juvenile myelomonocytic leukemia; MDS=myelodysplastic syndrome; AML=acute myeloid leukemia; ITP=immune thrombocytopenic purpura; AIHA=autoimmune hemolytic leukemia; TTP/HUS=thrombotic thrombocytopenic purpura/hemolytic–uremic syndrome; BMT=bone marrow transplant.
Back to article page